<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml>
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="0" size="22" family="Times" color="#000000"/>
	<fontspec id="1" size="8" family="Times" color="#000000"/>
	<fontspec id="2" size="7" family="Times" color="#000000"/>
<text top="23" left="55" width="517" height="33" font="0"><b>ENCODE DCC Antibody Validation Document</b></text>
<text top="77" left="48" width="81" height="12" font="1">Date of Submission</text>
<text top="347" left="39" width="41" height="12" font="1">Antibody </text>
<text top="359" left="39" width="52" height="12" font="1">Description: </text>
<text top="371" left="39" width="2" height="12" font="1"> </text>
<text top="485" left="84" width="61" height="12" font="1">Species Target</text>
<text top="521" left="84" width="90" height="12" font="1">Validation Method #1</text>
<text top="134" left="291" width="25" height="12" font="1">Email:</text>
<text top="134" left="48" width="27" height="12" font="1">Name:</text>
<text top="215" left="48" width="68" height="12" font="1">Antibody Name:</text>
<text top="215" left="300" width="29" height="12" font="1">Target:</text>
<text top="170" left="192" width="15" height="12" font="1">Lab</text>
<text top="249" left="183" width="44" height="12" font="1">Company/</text>
<text top="261" left="183" width="31" height="12" font="1">Source:</text>
<text top="485" left="300" width="53" height="12" font="1">Species Host</text>
<text top="300" left="336" width="50" height="12" font="1">Lot Number</text>
<text top="294" left="39" width="172" height="12" font="1">Catalog Number, database ID, laboratory </text>
<text top="306" left="39" width="2" height="12" font="1"> </text>
<text top="521" left="300" width="90" height="12" font="1">Validation Method #2</text>
<text top="555" left="84" width="50" height="12" font="1">Purification </text>
<text top="567" left="84" width="33" height="12" font="1">Method</text>
<text top="555" left="300" width="48" height="12" font="1">Polyclonal/ </text>
<text top="567" left="300" width="50" height="12" font="1">Monoclonal</text>
<text top="626" left="30" width="58" height="12" font="1">Reference (PI/</text>
<text top="638" left="30" width="49" height="12" font="1">Publication </text>
<text top="650" left="30" width="52" height="12" font="1">Information)</text>
<text top="674" left="28" width="294" height="12" font="1">Please complete the following for antibodies to histone modifications: </text>
<text top="687" left="28" width="205" height="11" font="2">if your specifications are not listed in the drop-down box,  </text>
<text top="697" left="28" width="155" height="11" font="2">please write-in the appropriate information</text>
<text top="728" left="30" width="59" height="12" font="1">Histone Name</text>
<text top="728" left="156" width="52" height="12" font="1">AA modified</text>
<text top="728" left="327" width="48" height="12" font="1">AA Position</text>
<text top="728" left="444" width="53" height="12" font="1">Modification</text>
<text top="419" left="39" width="29" height="12" font="1">Target </text>
<text top="431" left="39" width="52" height="12" font="1">Description: </text>
<text top="443" left="39" width="2" height="12" font="1"> </text>
<text top="599" left="165" width="51" height="12" font="1">Vendor URL:</text>
<text top="77" left="138" width="43" height="12" font="1">7/31/2011</text>
<text top="359" left="94" width="401" height="12" font="1">epitope corresponding to amino acids 1-96 mapping at the N-terminus of ATF-2 of human origin</text>
<text top="485" left="150" width="31" height="12" font="1">Human</text>
<text top="521" left="178" width="53" height="12" font="2">Western Blot</text>
<text top="134" left="326" width="182" height="12" font="1">Nathan_Lamarre-Vincent@hms.harvard.edu</text>
<text top="134" left="83" width="102" height="12" font="1">Nathan Lamarre-Vincent</text>
<text top="215" left="121" width="41" height="12" font="1">Anti-ATF2</text>
<text top="215" left="339" width="21" height="12" font="1">ATF2</text>
<text top="170" left="230" width="25" height="12" font="1">Struhl</text>
<text top="255" left="239" width="107" height="12" font="1">Santa Cruz Biotechnology</text>
<text top="485" left="361" width="27" height="12" font="1">Rabbit</text>
<text top="300" left="215" width="32" height="12" font="1">sc-6233</text>
<text top="521" left="395" width="19" height="12" font="2">ChIP</text>
<text top="561" left="141" width="48" height="12" font="2">Protein A/G</text>
<text top="561" left="356" width="43" height="12" font="2">Polyclonal</text>
<text top="413" left="94" width="424" height="12" font="1">ATF2 is a bZip transcription factor from the CREB family.  ATF2 binds to both cAMP response elements </text>
<text top="425" left="94" width="450" height="12" font="1">(TGACGTCA) and TPA responsive element (TGAGTCA) and is known to heterodimerize with JUN members of </text>
<text top="437" left="94" width="448" height="12" font="1">the AP1 family of transcription factors. ATF2 is activated by phosphorylation of Thr71 by the stress activated </text>
<text top="449" left="94" width="162" height="12" font="1">p38 mitogen activated protein kinases.</text>
<text top="599" left="238" width="183" height="12" font="1">http://www.scbt.com/datasheet-6233-atf-2-</text>
<text top="611" left="238" width="81" height="12" font="1">n-96-antibody.html</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="792" width="612">
<text top="146" left="52" width="57" height="12" font="1">Validation #1 </text>
<text top="158" left="52" width="34" height="12" font="1">Analysis</text>
<text top="661" left="50" width="143" height="12" font="1">Insert Validation Image (click here)</text>
<text top="152" left="125" width="318" height="12" font="1">Western blot analysis shows a single major band of the expected size ~70kD.</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="792" width="612">
<text top="159" left="57" width="57" height="12" font="1">Validation #2 </text>
<text top="171" left="57" width="34" height="12" font="1">Analysis</text>
<text top="643" left="54" width="145" height="12" font="1">Insert Validation Image (Click here)</text>
<text top="99" left="130" width="407" height="12" font="1">ATF2 ChIP-Seq analysis supports successful ChIP. A 19% of MACS-called ChIP-Seq peaks are found </text>
<text top="111" left="130" width="409" height="12" font="1">within 200bp of a known TSS.  ATF2 peaks preferentially overlap with the transcription factors JUN </text>
<text top="123" left="130" width="392" height="12" font="1">and  CREB. B De novo motif discovery with the MEME suite of analysis software using 100bp of </text>
<text top="135" left="130" width="417" height="12" font="1">sequence flanking the top 1000 ATF2 peaks identifies the TRE (p-value &lt; 8.85e-5) and CRE (p-value &lt; </text>
<text top="147" left="130" width="416" height="12" font="1">1.27e-3) motifs as enriched DNA elements. 19.8% of ATF2 peaks are associated with a TRE (p-value &lt; </text>
<text top="159" left="130" width="411" height="12" font="1">0.0001) relative to 4.6% of non-redundant RefSeq TxStart sites (p-valuebonf &lt;  3e-300), and 9.9% of </text>
<text top="171" left="130" width="394" height="12" font="1">ATF2 peaks are associated with a CRE relative to 8.6% of non-redundant RefSeq TxStart sites (p-</text>
<text top="183" left="130" width="387" height="12" font="1">valuebonf &lt; 0.01). ATF2 peak maxima and motif position are coincident. C ATF2 is specifically </text>
<text top="195" left="130" width="417" height="12" font="1">immunoprecipitated by ATF2 antibody (Santa Cruz sc-6233) and co-precipitates with JUN, JUNB and </text>
<text top="207" left="130" width="424" height="12" font="1">JUND but not CREB consistent with the documented ability of ATF2 to dimerize with the JUN family of </text>
<text top="219" left="130" width="88" height="12" font="1">transcription factors. </text>
<text top="695" left="268" width="68" height="12" font="1">Submit by Email</text>
</page>
</pdf2xml>
